3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
98
Carcinoma, Non-Small-Cell Lung
32
Neoplasms
22
Neoplasm Metastasis
14
Carcinoma, Renal Cell
13
Prostatic Neoplasms
12
Lung Neoplasms
12
Small Cell Lung Carcinoma
10
Diabetes Mellitus, Insulin-Dependent, 12
10
Pancreatic Neoplasms
7
Uveal Melanoma
6
Skin Neoplasms
6
Ovarian Neoplasms
6
Brain Neoplasms
6
Advanced Cancer
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Mesothelioma
5
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Kidney Neoplasms
4
Hodgkin Disease
4
Head and Neck Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Merkel Cell
4
Carcinoma, Hepatocellular
4
Carcinoma
4
Breast Neoplasms
4
Various Advanced Cancer
3
Interventions
Gemcitabine
4
Fluorouracil
4
dehydroftorafur
3
Taxes
3
Oxaliplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
Radiotherapy
2
Leucovorin
2
Irinotecan
2
tocilizumab
1
selicrelumab
1
niraparib
1
indusatumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Surgical Procedures, Operative
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiation
1
Pancreatectomy
1
PEGPH20
1
Nivolumab
1
Losartan
1
Ipilimumab
1
Folfox protocol
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pancreatic Adenocarcinoma
×
Ipilimumab
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts